An executive at Samsung is issued an arrest warrant, as prosecutors in South Korea continue to look into the accounting case leading up the IPO of Samsung BioLogics.
Fujifilm Life Science Strategic Business Office will open a site in Cambridge, Massachusetts in an aim to further link up with the surrounding pharmaceutical and biotech community.
Bluebird has received EU conditional marketing approval for patients with transfusion-dependent β-thalassemia, becoming the first treatment from its pipeline to receive approval.
The private equity firm Ampersand Capital has acquired Vibalogics with plans to increase development and manufacturing capabilities for complex viral products.
Novartis receives US FDA approval for its gene therapy, Zolgensma, which is a treatment for spinal muscular atrophy, and prices the drug at $2.1m per patient.
The Senate has passed a bill authorising spending on the development of products to protect the US against pandemic influenza and other biological threats to public health.
Celltrion plans to invest across its pharmaceutical business up to 2030, creating an estimated 110,000 new jobs in the process and launching 20 products.
Roche’s acquisition of Spark was announced at the start of the year but closing the deal has proved difficult after a third delay incurred to give the FTC extra review time.
A PhRMA report outlined the benefits that are brought to the US economy by the biopharmaceutical manufacturing industry, including revealing where the majority of facilities are located.
Dupixent, Regeneron and Sanofi’s collaborative mAb treatment for eczema, has been approved by the European Commission for a new indication in severe asthma.
This month’s round-up of the most popular stories of the month, featuring a bold prediction of future growth for Chinese biotech and bad news for a potential treatment for Alzheimer’s disease.
Biogen will halt all clinical trial activity on its Alzheimer’s drug, aducanumab, after its failure in Phase III trials, according to its first quarter financials.
UK-based investors launch Start Codon to recruit up to 50 start-up biotech companies for investment and risk mitigation opportunities over the next five years.
AbbVie receives approval from the US FDA for its newest psoriasis drug, Skyrizi, which looks set to recoup some of Humira’s revenue when it loses patent protection.
CPhI North America donates $10,000 to iBIO’s Educate Center to help fund STEM programs for girls and solidifies its partnership with the association to support Illinois as a growing life sciences hub.
Fuji Pharma signs agreement to receive an exclusive supply of the ustekinumab biosimilar for the Japanese market, furthering a previous investment agreement.
The industry focuses investments where there is the highest potential returns, but one panel at BIO-Europe Spring suggested multiple partners could boost outcomes in underserved therapeutic areas.
Regeneron and Alnylam sign discovery agreement that could advance 30 targets within CNS and ocular disorders, during an initial five-year discovery period.
As we enter spring, several companies have refreshed the look of their executive boards – some to strengthen their direction and some out of necessity.
Cell One Partners formally launches its consulting services and aims to be a long-term partner to its clients, supporting the development of cell and gene therapies – a market which raised more than $13.3bn in 2018.
The difficulties in the manufacture of CAR-T treatments have become increasingly understood as the breakthrough technology has been commercialised, but Kite’s head of medical affairs says its process is nearly flawless.
Thermo Fisher Scientific bolsters its gene therapy capabilities by acquiring Brammer Bio for $1.7bn, as the market becomes an ‘increasing focus’ for customers.
Biogen and its partner, Eisai, confirm a decision to stop the Phase III development of aducanumab, a potential treatment for Alzheimer’s – a key part of the former’s pipeline.
